首页> 美国卫生研究院文献>Blood >Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment low GVHD and durable remissions
【2h】

Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment low GVHD and durable remissions

机译:结合单倍体和脐带血移植降低强度调节可导致快速植入低GVHD和持久缓解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We conducted a 45 patient prospective study of reduced-intensity conditioning (RIC) and transplantation of unrelated umbilical cord blood (UCB) and CD34+ stem cells from a haploidentical family member. Median age was 50 years; weight was 80 kg. Fifty-eight percent had active disease. Neutrophil engraftment occurred at 11 days (interquartile range [IQR], 9-15) and platelet engraftment at 19 days (IQR, 15-33). In the majority of patients, early haploidentical engraftment was replaced by durable engraftment of UCB by 100 days, with regular persistence of minor host and/or haplo-hematopoiesis. Percentage of haplochimerism at day 100 correlated with the haplo-CD34 dose (P = .003). Cumulative incidence of acute GVHD (aGVHD) was 25% and chronic GVHD (cGVHD) was 5%. Actuarial survival at 1 year was 55%, progression-free survival (PFS) was 42%, nonrelapse mortality (NRM) was 28%, and relapse was 30%. RIC and haplo-cord transplantation results in fast engraftment of neutrophils and platelets, low incidences of aGVHD and cGVHD, low frequency of delayed opportunistic infections, reduced transfusion requirements, shortened length of hospital stay, and promising long-term outcomes. UCB cell dose had no impact on time to hematopoietic recovery. Therefore, UCB selection can prioritize matching, and better matched donors can be identified rapidly for most patients. This study is registered at as NCI clinical trial no. .
机译:我们进行了一项45位患者的前瞻性研究,研究对象为单倍家族成员的低强度调节(RIC)以及不相关的脐带血(UCB)和CD34 + 干细胞的移植。中位年龄为50岁;重量为80公斤。 58%患有活动性疾病。中性粒细胞植入发生在第11天(四分位间距[IQR],9-15),血小板植入发生在第19天(IQR,15-33)。在大多数患者中,早期单倍体植入被UCB持久植入100天所取代,并定期坚持较小的宿主和/或单倍血细胞生成。第100天的单倍嵌合率与单倍CD34剂量相关(P = 0.003)。急性GVHD(aGVHD)的累积发生率为25%,慢性GVHD(cGVHD)的累积发生率为5%。 1年时的精算生存率为55%,无进展生存期(PFS)为42%,非复发死亡率(NRM)为28%,复发率为30%。 RIC和单倍体线移植可导致中性粒细胞和血小板的快速植入,aGVHD和cGVHD的发生率低,延迟性机会感染的发生率低,输血需求减少,住院时间缩短以及长期前景良好。 UCB细胞剂量对造血恢复时间没有影响。因此,选择UCB可以优先考虑匹配,并且可以为大多数患者迅速找到匹配程度更高的供体。该研究注册为NCI临床试验No. 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号